PetriDish MedSafePre-prescription risk stratification · v1.0Guideline implemented
Catch medication risk before
the prescription reaches the patient.
One auditable report combining genotype, laboratory values, patient factors and concurrent medicines. Deterministic guideline rules — no LLM in the disposition path. Every reason cites its source (CPIC or approved product information); missing critical data blocks the disposition rather than producing false reassurance.
Never outputs
- "Safe" or "unsafe" verdicts
- A dose the prescriber can adopt without review
- A drug–gene relationship not in the encoded rule set
Always outputs
- Neutral 5-state disposition
- Every reason cites CPIC or approved product information
- Missing-critical-data list (blocks disposition when populated)
- rule_version + trace_id + clinician-review flag
Structured input · JSON
Deterministic rules · sub-second · zero LLM in disposition path
Phase-1 scope
Start narrow. Validate deeply.
Selected NSAIDs
Ibuprofen, naproxen, diclofenac, celecoxib, aspirin. Rules: eGFR, GI-bleed history, concurrent anticoagulant/antiplatelet, heart failure, age × duration, pregnancy trimester, CYP2C9 (ibuprofen, celecoxib).
Codeine · tramadol
CYP2D6 phenotype (CPIC), age contraindications, concurrent CNS depressants, elderly caution.
Paracetamol
Daily-dose ceiling, chronic alcohol / liver disease adjustment, duplicate-ingredient detection across Indian combination products.
Validation state ladder
Guideline implementedRule encoded and unit-tested
Not yet retrospectively or prospectively evaluated in an Indian cohort. The next state — retrospectively evaluated — requires 200–500 de-identified cases + one lab or hospital partner + independent clinician adjudication.